1. At a Glance
Torrent Pharma just flexed its balance sheet – ₹548 Cr profit in Q1 FY26, 11% sales growth, and a blockbuster ₹11,917 Cr acquisition of J.B. Chemicals stake. The company also raised its borrowing limit to ₹26,000 Cr because apparently, shopping is their new cardio.
2. Introduction
Imagine a pharma player that doesn’t just make pills, it swallows entire companies for breakfast. Torrent Pharma, the flagship of the Torrent Group, is doing exactly that – strong margins (32% OPM), a fat dividend policy, and a global playbook that’s working.
3. Business Model – WTF Do They Even Do?
- Branded Generics: 74% revenue share, across India & Brazil.
- Therapeutics: Cardio, CNS, diabetes, dermatology – all the boring but money-making segments.
- Growth Lever: Expansion in chronic therapies, R&D, and global acquisitions.
4. Financials Overview
